Announcements
- Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
- Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
- Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
More ▼
Key statistics
On Friday, Gyre Therapeutics Inc (L9S:FRA) closed at 9.60, 256.74% above the 52 week low of 2.69 set on Jun 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.60 |
---|---|
High | 9.60 |
Low | 9.60 |
Bid | 10.50 |
Offer | 10.60 |
Previous close | 9.10 |
Average volume | 213.80 |
---|---|
Shares outstanding | 85.51m |
Free float | 15.62m |
P/E (TTM) | -- |
Market cap | 971.39m USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:08 BST.
More ▼